Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s732, 2026. DOI: 10.25251/v9pqj003. Disponível em: https://skin.dermsquared.com/skin/article/view/4025. Acesso em: 27 apr. 2026.